Adbiotech Receives "Unqualified" Audit Opinion for Last Year... Strengthening Financial Stability and Securing Growth Foundations

Adbiotech announced that it has confirmed its financial soundness after receiving an "unqualified" opinion from its external auditor on last year's financial statements.

On March 23, the company disclosed this information through its audit report, explaining that it is pursuing a range of strategies to both maintain the stability of its existing business and improve its financial structure while also securing mid- to long-term growth engines.

The company also stated that, considering its current cash and cash equivalents, it has sufficient capacity to respond to short-term liquidity needs.

Adbiotech is also in the process of a paid-in capital increase to expand its capital base. Through this, the company plans to strengthen its financial stability, secure operating funds, and lay the foundation for new business initiatives.

Adbiotech is a healthcare company that manufactures and sells veterinary pharmaceuticals, feed additives, and health functional foods based on biotechnology. The company possesses a portfolio of disease response products directly linked to productivity at livestock sites, and recently confirmed the efficacy of an antibody therapy against highly mutated avian influenza (AI) viruses.

A company representative stated, "Given our current liquidity, ongoing capital expansion, and preparations for new businesses, we expect company operations to remain stable. We will focus on both stabilizing our financial structure and securing new growth engines to alleviate market concerns and enhance corporate value."

This content was produced with the assistance of AI translation services.